Medicare AdvantageBilling CodesHigh impact
MA08.148d, Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Independence Blue Cross is updating coding for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) effective July 1, 2026. Two unclassified codes (C9399 and J3590) are being removed and replaced with a single specific HCPCS code J9062. Billing teams must update their systems to use the new code for all Rybrevant Faspro claims to avoid denials.
Action Required
By June 30, 2026: Billing team must update billing system and claims software to remove codes C9399 and J3590 from Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) claims and replace with HCPCS code J9062. Update all claim templates, billing protocols, and provider encounter forms to reflect the new code. Communicate change to oncology providers and infusion centers. Effective July 1, 2026, all Rybrevant Faspro claims submitted with old codes C9399 or J3590 will be denied. Continue using J9061 for amivantamab-vmjw (Rybrevant) IV formulation.